Sedana Medical AB (publ), Interim Report, Q3, July-September 2017: Continued strong sales growth and registration study for Europe according to plan
Financial summaryJuly-September · Net sales during the third quarter amounted to 10,191 (7,603) KSEK, corresponding to an increase of 34% compared with the same period in 2016. · Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to -980 (-381) KSEK. This corresponds to an EBITDA margin of -9.6% (-5.0%). · Earnings before interest and taxes (EBIT) amounted to -2,254 (-511) KSEK, which corresponds to an EBIT margin of -22.1% (-6.7%). · Cash flow from operations before changes in working capital amounted to -1,862 (181) KSEK. ·